News

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...
Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...
Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...
Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the ...
The manufacturer of Mounjaro has responded to dangerous hack that’s been doing the rounds on social media. Videos of people ...
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...
Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...
The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...
Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...
Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...
Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...
The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...